Liver-specific expression of dominant- negative transcription factor 7-like 2 causes progressive impairment in glucose homeostasis

Diabetes

Volumn 64, Issue 6, 2015, Pages 1923-1932

  Ip, Wilfred ^a,b   Shao, Weijuan ^b   Song, Zhuolun ^b   Chen, Zonglan ^b,c   Wheeler, Michael B ^a   Jin, Tianru ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROGLUCAGON; PYRUVIC ACID; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR FKHR; WNT3A PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, MOUSE;

ADENOVIRIDAE; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE REPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN BLOOD LEVEL; LIVER; LIVER CELL; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; C57BL MOUSE; GENETICS; HOMEOSTASIS; HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; BETA CATENIN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GLUCOSE; HOMEOSTASIS; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN;

EID: 84924320470     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1329     Document Type: Article

References (50)

1. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7- like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-323.
2. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007; 117:2155-2163.
3. Schäfer SA, Tschritter O, Machicao F, et al. Impaired glucagon-like peptide- 1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007;50:2443-2450.
4. Shu L, Sauter NS, Schulthess FT, Matveyenko AV, Oberholzer J, Maedler K. Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. Diabetes 2008;57:645-653.
5. da Silva Xavier G, Loder MK, McDonald A, et al. TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells. Diabetes 2009;58: 894-905.
6. Savic D, Ye H, Aneas I, Park SY, Bell GI, Nobrega MA. Alterations in TCF7L2 expression define its role as a key regulator of glucose metabolism. Genome Res 2011;21:1417-1425.
7. Boj SF, van Es JH, Huch M, et al. Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell 2012;151:1595-1607.
8. Norton L, Fourcaudot M, Abdul-Ghani MA, et al. Chromatin occupancy of transcription factor 7-like 2 (TCF7L2) and its role in hepatic glucose metabolism. Diabetologia 2011;54:3132-3142.
9. da Silva Xavier G, Mondragon A, Sun G, et al. Abnormal glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-null mice. Diabetologia 2012; 55:2667-2676.
10. Ip W, Shao W, Chiang YT, Jin T. The Wnt signaling pathway effector TCF7L2 is upregulated by insulin and represses hepatic gluconeogenesis. Am J Physiol Endocrinol Metab 2012;303:E1166-E1176.
11. Oh KJ, Park J, Kim SS, Oh H, Choi CS, Koo SH. TCF7L2 modulates glucose homeostasis by regulating CREB- And FoxO1-dependent transcriptional pathway in the liver. PLoS Genet 2012;8:e1002986.
12. Shao W, Wang D, Chiang YT, et al. The Wnt signaling pathway effector TCF7L2 controls gut and brain proglucagon gene expression and glucose homeostasis. Diabetes 2013;62:789-800.
13. Shu L, Zien K, Gutjahr G, et al. TCF7L2 promotes beta cell regeneration in human and mouse pancreas. Diabetologia 2012;55:3296-3307.
14. Chiang YT, Ip W, Shao W, Song ZE, Chernoff J, Jin T. Activation of GLP-1 signaling attenuates impaired hepatic glucose disposal in aged male p21- Activated protein kinase-1 knockout mice. Endocrinology 2014;155:2122-2132.
15. Liu Z, Habener JF. Wnt signaling in pancreatic islets. Adv Exp Med Biol 2010;654:391-419.
16. Liu Z, Habener JF. Stromal cell-derived factor-1 promotes survival of pancreatic beta cells by the stabilisation of beta-catenin and activation of transcription factor 7-like 2 (TCF7L2). Diabetologia 2009;52:1589-1598.
17. Neve B, Le Bacquer O, Caron S, et al. Alternative human liver transcripts of TCF7L2 bind to the gluconeogenesis regulator HNF4a at the protein level. Diabetologia 2014;57:785-796.
18. McCarthy MI, Rorsman P, Gloyn AL. TCF7L2 and diabetes: A tale of two tissues, and of two species. Cell Metab 2013;17:157-159.
19. Nobrega MA. TCF7L2 and glucose metabolism: Time to look beyond the pancreas. Diabetes 2013;62:706-708.
20. Murtaugh LC, Law AC, Dor Y, Melton DA. Beta-catenin is essential for pancreatic acinar but not islet development. Development 2005;132:4663-4674.
21. Lehwald N, Tao GZ, Jang KY, Sorkin M, Knoefel WT, Sylvester KG. Wntbeta- catenin signaling protects against hepatic ischemia and reperfusion injury in mice. Gastroenterology 2011;141:707-718, 718.e1-e5.
22. Lehwald N, Tao GZ, Jang KY, et al. b-Catenin regulates hepatic mitochondrial function and energy balance in mice. Gastroenterology 2012;143:754-764.
23. Tao GZ, Lehwald N, Jang KY, et al. Wnt/b-catenin signaling protects mouse liver against oxidative stress-induced apoptosis through the inhibition of forkhead transcription factor FoxO3. J Biol Chem 2013;288:17214-17224.
24. Zhang XF, Tan X, Zeng G, et al. Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: Role of oxidative stress and plateletderived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology 2010;52:954-965.
25. Debies MT, Gestl SA, Mathers JL, et al. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. J Clin Invest 2008;118:51-63.
26. Nejak-Bowen K, Kikuchi A, Monga SP. Beta-catenin-NF-kB interactions in murine hepatocytes: A complex to die for. Hepatology 2013;57:763-774.
27. Clevers H, Nusse R. Wnt/b-catenin signaling and disease. Cell 2012;149: 1192-1205.
28. Rajagopal J, Carroll TJ, Guseh JS, et al. Wnt7b stimulates embryonic lung growth by coordinately increasing the replication of epithelium and mesenchyme. Development 2008;135:1625-1634.
29. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, Korswagen HC. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 2005;308:1181-1184.
30. Manolagas SC, Almeida M. Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 2007;21:2605-2614.
31. Iyer S, Ambrogini E, Bartell SM, et al. FOXOs attenuate bone formation by suppressing Wnt signaling. J Clin Invest 2013;123:3409-3419.
32. Liu H, Fergusson MM, Wu JJ, et al. Wnt signaling regulates hepatic metabolism. Sci Signal 2011;4:ra6.
33. Pinkert CA, Ornitz DM, Brinster RL, Palmiter RD. An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liverspecific expression in transgenic mice. Genes Dev 1987;1:268-276.
34. Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase- 3beta. J Biol Chem 2005;280:1457-1464.
35. Kolligs FT, Hu G, Dang CV, Fearon ER. Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol 1999;19:5696-5706.
36. Takamoto I, Kubota N, Nakaya K, et al. TCF7L2 in mouse pancreatic beta cells plays a crucial role in glucose homeostasis by regulating beta cell mass. Diabetologia 2014;57:542-553.
37. Shao W, Wang Z, Ip W, et al. GLP-1(28-36) improves b-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/b-catenin signaling in b-cells in vitro. Am J Physiol Endocrinol Metab 2013; 304:E1263-E1272.
38. Ip W, Shao W, Chiang YT, Jin T. GLP-1-derived nonapeptide GLP-1(28- 36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice. Am J Physiol Endocrinol Metab 2013; 305:E1348-E1358.
39. Wang P, Wang Q, Sun J, et al. POU homeodomain protein Oct-1 functions as a sensor for cyclic AMP. J Biol Chem 2009;284:26456-26465.
40. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-1787.
41. Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 2008;283:8723-8735.
42. Hall RK, Yamasaki T, Kucera T, Waltner-Law M, O'Brien R, Granner DK. Regulation of phosphoenolpyruvate carboxykinase and insulin-like growth factorbinding protein-1 gene expression by insulin. The role of winged helix/forkhead proteins. J Biol Chem 2000;275:30169-30175.
43. Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest 2001;108:1359-1367.
44. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445:881-885.
45. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007;316:1341-1345.
46. Saxena R, Voight BF, Lyssenko V, et al.; Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316:1331-1336.
47. Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- And GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 2009;18:2388-2399.
48. Brannon M, Brown JD, Bates R, Kimelman D, Moon RT. XCtBP is a XTcf-3 co-repressor with roles throughout Xenopus development. Development 1999; 126:3159-3170.
49. Brantjes H, Roose J, van De Wetering M, Clevers H. All Tcf HMG box transcription factors interact with Groucho-related co-repressors. Nucleic Acids Res 2001;29:1410-1419.
50. Roose J, Molenaar M, Peterson J, et al. The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 1998;395:608-612.